TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11585606

Group type: EXPERIMENTAL
Intervention: 200 mg of T enanthate i.m. weekly for 8 weeks (active group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 200 mg of sodium chloride i.m. weekly for 8 weeks (placebo group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 200 mg T enanthate i.m. bi-weekly for 8 weeks (hypogonadal group)
Number of subjects: 37
Study: 9823478

Group type: EXPERIMENTAL
Intervention: Visual n-back working memory task (n = 1, 2, 3)
Number of subjects: 8
Study: 8008347

Group type: EXPERIMENTAL
Intervention: Vitreous surgery (vitrectomy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 62
Study: 2478601

Group type: EXPERIMENTAL
Intervention: Tape-slide series using a desensitization and modeling approach
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Heart rate measurement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Modified Melamed's scale
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subjective dentist's evaluation
Number of subjects: 28
Study: 177372

Group type: EXPERIMENTAL
Intervention: pivmecillinam
Number of subjects: 52

Group type: COMPARATOR
Intervention: pivampicillin
Number of subjects: 52

Group type: COMPARATOR
Intervention: alternating treatment of pivmecillinam and pivampicillin
Number of subjects: 52
Study: 28597308

Group type: EXPERIMENTAL
Intervention: Boosted telephone follow-up after occupational rehabilitation program
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no boosted follow-up)
Number of subjects: 213
Study: 25721464

Group type: EXPERIMENTAL
Intervention: Individualized lifestyle and life skills intervention (12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 28
Study: 23851034

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 135
Study: 22101426

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention focusing on self-management, delivered by a clinical pharmacist, with structured education about COPD and management of its symptoms.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 133
Study: 19897470

Group type: EXPERIMENTAL
Intervention: Any gastrointestinal infection in infancy
Number of subjects: 13089

Group type: EXPERIMENTAL
Intervention: Hospitalisation for gastrointestinal infection in infancy
Number of subjects: 13089

Group type: EXPERIMENTAL
Intervention: Hospitalisation for gastrointestinal infection in infancy or childhood
Number of subjects: 13089
Study: 19453396

Group type: EXPERIMENTAL
Intervention: H5 live influenza vaccine (A/17/Duck/Potsdam/86/92 (H5N2)), administered intranasally in two doses 21 days apart.
Number of subjects: 0
Study: 15570576

Group type: EXPERIMENTAL
Intervention: Tolterodine (TOL) 4 mg daily for 8 weeks
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Tolterodine (TOL)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 743
Study: 12882824

Group type: EXPERIMENTAL
Intervention: Fish oil (DHA) supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo oleic acid dietary supplement
Number of subjects: 100
Study: 10848656

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 286

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 286
Study: 8855733

Group type: EXPERIMENTAL
Intervention: Omeprazole (4 weeks)
Number of subjects: 72
Study: 1463867

Group type: EXPERIMENTAL
Intervention: Interval cancers
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control cancers
Number of subjects: 333
Study: 3155806

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (125 mg, 0.5 mL injection)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Spectinomycin (2 g injection)
Number of subjects: 84
Study: 31628248

Group type: EXPERIMENTAL
Intervention: Interactive smartphone application promoting condom use over 180 days
Number of subjects: 433

Group type: COMPARATOR
Intervention: Dummy application (control group)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Both groups received standard of care at the Youth Health Clinics (YHC)
Number of subjects: 433
Study: 29248640

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg for 6 months (n = 51)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo for 6 months (n = 54)
Number of subjects: 194
Study: 30517723

Group type: EXPERIMENTAL
Intervention: Ingestion of 500 mL beer
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ingestion of 500 mL soda
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ingestion of 500 mL beer and soda
Number of subjects: 34
Study: 27005463

Group type: EXPERIMENTAL
Intervention: 100 mg anamorelin
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 50 mg anamorelin
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 24886581

Group type: EXPERIMENTAL
Intervention: Early specific cognitive-behavioural psychotherapy (CBT) including stress management and problem solving strategies, with elements of mindfulness-based therapy (MBT) for 14 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unstructured group meetings for 14 weeks.
Number of subjects: 0
Study: 22696845

Group type: EXPERIMENTAL
Intervention: 0, 5-min instillation (Method A) of combined 0.75% tropicamide and 2.5% phenylephrine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0, 30-min instillation (Method B) of combined 0.75% tropicamide and 2.5% phenylephrine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 42
Study: 21035693

Group type: EXPERIMENTAL
Intervention: Remote superficial femoral artery endarterectomy (RSFAE)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Supragenicular bypass surgery
Number of subjects: 116
Study: 18532970

Group type: EXPERIMENTAL
Intervention: Early catheter removal (immediate removal after surgery)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (catheter removed at least 24 hours after surgery)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Early catheter removal
Number of subjects: 90
Study: 16053475

Group type: EXPERIMENTAL
Intervention: subcutaneous interferon (IFN) beta‐1a, 22 or 44 mug three times weekly
Number of subjects: 560

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 560
Study: 11834004

Group type: EXPERIMENTAL
Intervention: Diuretics (fusemide and amiloride)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 12198785

Group type: EXPERIMENTAL
Intervention: Image generation task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Image maintenance task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scanning task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotation task
Number of subjects: 0
Study: 7487445

Group type: EXPERIMENTAL
Intervention: Walking cadence at 120 steps/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Walking cadence at 70 steps/min
Number of subjects: 8
Study: 1819543

Group type: EXPERIMENTAL
Intervention: Lisuride (0.1 mg, 1/2 tablet every 8 hours for 3 months)
Number of subjects: 23
Study: 6128451

Group type: EXPERIMENTAL
Intervention: Increased oral potassium 64 mmol a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30798684

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 0
Study: 29058620

Group type: EXPERIMENTAL
Intervention: POWERS forID intervention (access to the POWERS forID website and health coach calls)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard clinical weight-loss care (control group)
Number of subjects: 70
Study: 25207682

Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion (20% Intralipid®)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ringer's acetate solution
Number of subjects: 8
Study: 23475800

Group type: COMPARATOR
Intervention: Conventional 5-mm electrocautery hook (hook group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Double-lumen electrocautery tube (DLET group)
Number of subjects: 46
Study: 22526529

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) 400 mg/70 kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 and 0.5 mg/70 kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19106243

Group type: EXPERIMENTAL
Intervention: Protein supplementation (20 g protein/session) before and after exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (no protein supplementation)
Number of subjects: 26
Study: 17888735

Group type: EXPERIMENTAL
Intervention: irinotecan plus bevacizumab
Number of subjects: 56677

Group type: EXPERIMENTAL
Intervention: irinotecan plus oxaliplatin
Number of subjects: 56677

Group type: EXPERIMENTAL
Intervention: oxaliplatin plus bevacizumab
Number of subjects: 56677

Group type: EXPERIMENTAL
Intervention: bevacizumab alone
Number of subjects: 56677

Group type: EXPERIMENTAL
Intervention: oxaliplatin alone
Number of subjects: 56677

Group type: EXPERIMENTAL
Intervention: irinotecan plus cetuximab
Number of subjects: 56677

Group type: EXPERIMENTAL
Intervention: irinotecan alone
Number of subjects: 56677
Study: 15250565

Group type: EXPERIMENTAL
Intervention: 0.2% nitroglycerine (GTN)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 5% xylocaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Proctosedyl
Number of subjects: 64

Group type: COMPARATOR
Intervention: Petroleum jelly (Vaseline)
Number of subjects: 64
Study: 12495901

Group type: EXPERIMENTAL
Intervention: rHuG-CSF 10 mg/kg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control (no rHuG-CSF)
Number of subjects: 221
Study: 9667102

Group type: EXPERIMENTAL
Intervention: KH 1060 ointment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle only
Number of subjects: 10
Study: 9475569

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ebastine (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 24
Study: 1847023

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) at 3 ng.kg‐1.min‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) at 6 ng.kg‐1.min‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6341063

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Urografin (diatrizoate) 60%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Iohexol and Urografin
Number of subjects: 50
Study: 31790750

Group type: EXPERIMENTAL
Intervention: Nurse-led facilitated advance care planning (ACP) intervention
Number of subjects: 149
Study: 31376781

Group type: EXPERIMENTAL
Intervention: Question Formulation Technique (QFT) intervention
Number of subjects: 3173
Study: 30188451

Group type: EXPERIMENTAL
Intervention: Thermomechanical stimulation (Buzzy)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 105
Study: 27126336

Group type: EXPERIMENTAL
Intervention: Ectoine mouth and throat spray
Number of subjects: 95

Group type: COMPARATOR
Intervention: Saline lozenges
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 95
Study: 24572590

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acute anaerobic exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Athletes group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 22525773

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Life as usual
Number of subjects: 63

Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 63
Study: 20456625

Group type: EXPERIMENTAL
Intervention: Traditional sex therapy and/or gingko biloba
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sexually healthy women (control group)
Number of subjects: 99
Study: 17343668

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study: 15760426

Group type: EXPERIMENTAL
Intervention: Antifungal therapy for 2 weeks and 3 months
Number of subjects: 103

Group type: COMPARATOR
Intervention: Anti-retroviral agents
Number of subjects: 103
Study: 12409657

Group type: EXPERIMENTAL
Intervention: Unilateral neck exploration
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bilateral neck exploration
Number of subjects: 91
Study: 9045329

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 and paclitaxel 135 mg/m2
Number of subjects: 386

Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 and cyclophosphamide 750 mg/m2
Number of subjects: 386
Study: 8345115

Group type: EXPERIMENTAL
Intervention: Classroom instruction in body mechanics (2 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent study module
Number of subjects: 0
Study: 3490659

Group type: EXPERIMENTAL
Intervention: High frequency TENS for 15-20 minutes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with dilute local anesthetics
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 15
Study: 31617769

Group type: EXPERIMENTAL
Intervention: Paracetamol administration by parents after GP consultation
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Paracetamol administration in children aged three to six months
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Paracetamol administration in children aged five to twelve years
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Frequency of paracetamol administration for common infections
Number of subjects: 548
Study: 29402561

Group type: EXPERIMENTAL
Intervention: Immediate loading of the implant
Number of subjects: 158

Group type: COMPARATOR
Intervention: Delayed loading of the implant
Number of subjects: 158
Study: 26659706

Group type: COMPARATOR
Intervention: PEGIFN/RBV for 24 or 48 weeks depending on rapid virologic response (RVR)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: BOC add-on therapy at week 12 for patients without cEVR
Number of subjects: 19
Study: 24885958

Group type: EXPERIMENTAL
Intervention: Job rotation intervention group
Number of subjects: 957

Group type: COMPARATOR
Intervention: Control group (no job rotation)
Number of subjects: 957
Study: 22744547

Group type: EXPERIMENTAL
Intervention: Brace treatment for 18 hours/day
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Brace treatment for 21 hours/day
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Brace treatment for 23 hours/day
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 136

Group type: COMPARATOR
Intervention: Observed (Control)
Number of subjects: 136
Study: 20334677

Group type: EXPERIMENTAL
Intervention: Interceptor((R)) LLINs
Number of subjects: 398

Group type: COMPARATOR
Intervention: Conventionally treated nets (CTNs)
Number of subjects: 398
Study: 19031770

Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ordinary group
Number of subjects: 150
Study: 15925295

Group type: EXPERIMENTAL
Intervention: Omega-3 group (n = 9)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 21
Study: 12889696

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (no-gel control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Number of subjects: 50
Study: 10550566

Group type: EXPERIMENTAL
Intervention: Etoposide orally at 50 mg daily and cyclophosphamide orally at 50 mg daily (first cohort)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Etoposide orally at 50 mg twice daily and cyclophosphamide orally at 50 mg twice daily (second cohort)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 57
Study: 8889904

Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg orally once daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Erythromycin base 250 mg orally four times daily
Number of subjects: 39
Study: 1478125

Group type: EXPERIMENTAL
Intervention: Captopril (4-week treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril (3-day treatment)
Number of subjects: 30
Study: 6362830

Group type: EXPERIMENTAL
Intervention: BHD plus levamisole
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: BHD
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: High-dose DTIC plus actinomycin D
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: High-dose DTIC plus actinomycin D (with prior disease-free interval > 6 months)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Immunotherapy limb (BHD plus levamisole)
Number of subjects: 280
Study: 31687935

Group type: EXPERIMENTAL
Intervention: Implicit Learning Approach (ILA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study: 29469022

Group type: EXPERIMENTAL
Intervention: FTO risk allele (AA) in obese black women
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: GNB3 non-risk CC homozygotes
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: GNB3 C carriers (white women)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: GNB3 homozygote (TT) overweight women
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: FTO gene (obese carriers of the risk allele)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: GNB3 heterozygotes (CT)
Number of subjects: 774
Study: 25791446

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 60
Study: 24722262

Group type: EXPERIMENTAL
Intervention: Computer‐assisted cognitive training (60 hours over 10 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 34
Study: 21968714

Group type: EXPERIMENTAL
Intervention: Patient Control Analgesia (PCA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Morphine bolus
Number of subjects: 47
Study: 20016381

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 689
Study: 17492590

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 96
Study: 16198334

Group type: EXPERIMENTAL
Intervention: Ozone therapy (local and rectal insufflation of the gas)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Antibiotic therapy (topical and systemic)
Number of subjects: 101
Study: 12195347

Group type: EXPERIMENTAL
Intervention: HAART plus low-dose prolonged intermittent interleukin (IL)-2 (n=12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: HAART alone (n=10)
Number of subjects: 22
Study: 10363339

Group type: EXPERIMENTAL
Intervention: Statistical model examining treatment efficacy in randomized phase III trials with varying alpha levels and sample sizes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judicious choice of type I error rate and trial size.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall context of research setting and long-term goals in trial design.
Number of subjects: 0
Study: 7877932

Group type: EXPERIMENTAL
Intervention: New intestinal recording devices for assessing motility
Number of subjects: 0
Study: 2120310

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 443

Group type: COMPARATOR
Intervention: diatrizoate
Number of subjects: 443
Study: 131139

Group type: EXPERIMENTAL
Intervention: Thymoxamine or cromolyn sodium inhalation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 22
Study: 31671060

Group type: EXPERIMENTAL
Intervention: SVG-DES (Drug-Eluting Stent)
Number of subjects: 182

Group type: COMPARATOR
Intervention: SVG-MT (Medical Treatment)
Number of subjects: 182
Study: 28671091

Group type: EXPERIMENTAL
Intervention: dezocine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 1000
Study: 25795145

Group type: EXPERIMENTAL
Intervention: Step-Up to Quit (SUTQ) intervention that integrates advice for low-to-moderate intensity physical activity (LMPA) with standard smoking cessation counseling (SCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard smoking cessation counseling (SCC) control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Step-Up to Quit (SUTQ) intervention
Number of subjects: 0
Study: 23945243

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 46
Study: 20154213

Group type: EXPERIMENTAL
Intervention: MRD standard risk (MRD-SR) patients, n = 1348
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: MRD intermediate risk (MRD-IR) patients, n = 1647
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: MRD high risk (MRD-HR) patients, n = 189
Number of subjects: 3184
Study: 18277935

Group type: EXPERIMENTAL
Intervention: Breast-feeding infants at the 4-6 week visit (with negative HIV-1 results at that visit)
Number of subjects: 2052

Group type: EXPERIMENTAL
Intervention: More advanced maternal HIV-1 disease (lower CD4 counts, higher plasma viral loads)
Number of subjects: 2052
Study: 15721027

Group type: EXPERIMENTAL
Intervention: Hormone therapy (0.625 mg/day of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (400 IU of Vitamin E and 500 mg of Vitamin C twice daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo for hormone therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo for antioxidant vitamins
Number of subjects: 61
Study: 12893194

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg/m(2)/day days 1‐5) with Topotecan (1.25 mg/m(2)/day days 1‐5)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m(2)/day days 1‐5)
Number of subjects: 30
Study: 10534084

Group type: EXPERIMENTAL
Intervention: Flat tip cervical cryotherapy
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Shallow conical tip cervical cryotherapy
Number of subjects: 117